Department of Public Health and Human Services

Montana Healthcare Programs Provider Information » Drug Use Review (DUR) Board

Main Content

Drug Use Review (DUR) Board

Drug Use Review (DUR) Board
Formulary Committee

DUR Board Meeting Agendas

2017 Agendas

April 26, 2017 - PDL Revised 04/07/2017

- DOI Link, Feldman Int J Chron Obstruct Pulmon Dis

- Epclusa® Clinical Review Summary

- Taltz® Medical Value Summary

- EucrisaTM AMCP Dossier

- Med Info Letter Xeljanz® XR

- Montana Medicaid Final Chantix®

March 29, 2017 - PDL Revised 03/14/2017

Rexulti®

- Restasis®

- Aristada®

February 15, 2017 - PDL

- Chest Guidelines for VTE Servlet

- Entresto®

- Ocaliva® Letter

- Ocaliva® AMCP Dossier

- Summary Eliquis® Servlet

January 25, 2017 - DURB

2016 Agendas

September 28, 2016

August 31, 2016 Revised 08.18.2016

April 27, 2016 Revised 04.21.2016

- Dyanavel XR® Formulary Submission

- Pfizer Medical Information for QuilliChew ER C-II

- A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of SchizophreniaJ Clin Psychiatry Meltzer et al. 2015

March 30, 2016 Revised 03.09.2016

- Cosentyx ® (secukinumab) Clinic Summary

- Humira® (Adalimumab) Medicaid Testimony

- Seebri® Neohaler® (glycopyrrolate) inhalation powder Clinical Summary

- Technivie® (ombitasvir, paritaprevir, and ritonavir tablets) Medicaid Testimony

- Tudorza ® Pressair® (Aclidinium bromide inhalation powder) Clinical Executive Summary

- Utibron ® Neohaler® (indacaterol and glycopyrrolate) inhalation powder Clinical Summary

February 17, 2016

- Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension for AMBITION investigators  N Engl J Med 373;9 nejm.org August 27, 2015

Supplementary Appendix to Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension 

N Engl J Med 2015;373:834-44. DOI: 10.1056/NEJMoa1413687

- Entresto® (sacubitril and valsartan) Clinical Summary for Formulary Review

- Montana Medicaid Repatha (Evolucumab) Submission

- Movantik

January 20, 2016

2015 Agendas

October 28, 2015

September 30, 2015 Rev. 09.16.2015

April 29, 2015

- Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity:results from a randomized controlled trial in relapsing-remitting multiple sclerosis Arnold et al. BMC Neurology

- Bunavail® (Buprenorphine/naloxone)

- Hysingla® Formulary Dossier

- Lemtrada™

- Abilify® (aripiprazole) Testimony – Montana Medicaid

- Plegridy™ Summary Medicaid Pharmacy &Therapeutics Committee

- Suboxone® Sublingual Film

- Novel Buccal Film Formulation of Bupenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence:A 12-Week Conversion Study Sullivan and Webster, Clinical Therapeutics/2015

- Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures Fountain, et al.  Epilepsia, 54(1):58–65, 2013

March 25, 2015 Revised 03.04.2015

- Arnuity Product Summary

- Incruse Ellipta Prescribing Information

- Incruse Ellipta Product Summary

- Otezla Medicaid Summary

- Ruconest Dossier

February 18, 2015 Revised 02.10.2015

- Akynzeo® Formulary Dossier

- Trulicity™ Medical Value Summary, November 3, 2014

- Tanzeum™ Product Summary

- Viekira Pak® Medicaid Clinical Summary, December 2014

- Xigduo™ XR Clinical Summary, November 2014

January 28, 2015

2014 Agendas

October 15, 2014

September 17, 2014 Revised

April 23, 2014 Revised

- DUAVEE (Conjugated Estrogens/Bazedoxifene)

March 26, 2014

- TOVIAZ (fesoterodine fumarate)

- OLYSIO™ (simeprevir) Capsules, for Oral Use

- Product Summary for Breo Ellipta

February 19, 2014

- FYCOMPA™ (perampanel)

- INVOKANA™ (canagliflozin) Tablets, for Oral Use

- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension N Engl J Med 369;4 NEJM.org, July 25, 2013

January 29, 2014

DUR Board Meeting Minutes

To locate older documents, access the Archive Page.